Pharma and Biotech Patent Litigation Summit returns to Amsterdam with IPKat readers’ discount

Amsterdam Kat

The IPKat has learned that on, 22-24 January 2024, the Pharma and Biotech Patent Litigation Summit will return to the Anantara Grand Hotel Krasnapolsky in Amsterdam (Netherlands). A UPC Litigation Forum will take place on 22 January too.

This 3-day conference promises to offer 200+ private practice and in-house participants a forum of practical discussions surrounding the leading patent litigation topics in Europe, with a compare-and-contrast method with jurisdictions further afield.

According to the organizers, this internationally recognized summit will provide the necessary practical tools to defend patent litigation challenges for pharma and biotech products, whilst also maximizing litigation strategies to allow for successful IP protection. With the central case law and regulatory updates, this event focuses on the European market and those working within life science IP.

As the agenda also indicates, the following promise to be the highlights of this year’s edition:

• Form a holistic and practical UPC litigation strategy with a cross-industry case law review, a mock trial alongside leading judges and litigators and a pharma and biotech UPC strategy panel.
• Update one’s own pharma and biotech patent litigation strategy with the latest regulatory developments and case law regarding the doctrine of equivalents, second medical use, preliminary injunctions and divisional patent practice.
• Develop a transatlantic understanding of patentability concerns with an Amgen vs Sanofi case law review and an industry-panel concerning the G2/21 EPO Board of Appeals decision.
• Form a global understanding of the patent litigation ecosphere with a panel of judges from the UK, EPO, USA and the UPC.

The IPKat has negotiated a special discount for readers. By using IPKAT at checkout, a 10% discount in the registration fee will be applied. Click here for further details and to register.